237 related articles for article (PubMed ID: 24670051)
1. Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.
Li R; Du J; Hou J
Hematology; 2015 Jan; 20(1):11-7. PubMed ID: 24670051
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
Stelmach-Gołdyś A; Czarkowska-Paczek B
Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
[TBL] [Abstract][Full Text] [Related]
5. Emerging concepts in monoclonal gammopathy of undetermined significance.
Freytes CO
Bol Asoc Med P R; 2010; 102(4):43-6. PubMed ID: 21766546
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
7. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance.
Kyle RA; Rajkumar SV
Br J Haematol; 2006 Sep; 134(6):573-89. PubMed ID: 16938117
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
12. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.
Kristinsson SY; Björkholm M; Landgren O
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):187-90. PubMed ID: 23490991
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance: a consensus statement.
Berenson JR; Anderson KC; Audell RA; Boccia RV; Coleman M; Dimopoulos MA; Drake MT; Fonseca R; Harousseau JL; Joshua D; Lonial S; Niesvizky R; Palumbo A; Roodman GD; San-Miguel JF; Singhal S; Weber DM; Zangari M; Wirtschafter E; Yellin O; Kyle RA
Br J Haematol; 2010 Jul; 150(1):28-38. PubMed ID: 20507313
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal gammopathy of undetermined significance : when and why to look for them ?].
Meuleman N; Vercruyssen M
Rev Med Brux; 2018; 39(4):302-306. PubMed ID: 30320992
[TBL] [Abstract][Full Text] [Related]
15. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
Madan S; Greipp PR
Blood Rev; 2009 Nov; 23(6):257-65. PubMed ID: 19699016
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues.
Klincová M; Sandecká V; Mikuláiová A; Radocha J; Maisnar V; Hájek R
Klin Onkol; 2011; 24 Suppl():S14-7. PubMed ID: 21923058
[TBL] [Abstract][Full Text] [Related]
17. The clinical features and prognosis of the monoclonal gammopathy undetermined significance: A single center study.
Ma L; Xu S; Wen L; Liu Y; Kang Y; Huang X; Lu J
Blood Cells Mol Dis; 2018 Nov; 73():9-13. PubMed ID: 30195627
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
[TBL] [Abstract][Full Text] [Related]
19. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
Berenson JR; Yellin O
Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
